Current Diabetes Reports

, 14:483

Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

  • Angelo Avogaro
  • Saula Vigili de Kreutzenberg
  • Gian Paolo Fadini
Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

DOI: 10.1007/s11892-014-0483-3

Cite this article as:
Avogaro, A., Vigili de Kreutzenberg, S. & Fadini, G.P. Curr Diab Rep (2014) 14: 483. doi:10.1007/s11892-014-0483-3
Part of the following topical collections:
  1. Topical Collection on Pharmacologic Treatment of Type 2 Diabetes

Abstract

Incretin-based therapy became recently available as antihyperglycemic treatment for patients with type 2 diabetes (T2DM). Incretin therapy comprises glucagon-like peptide receptor agonists (GLP-1RA) and dipeptidyl-peptidase 4 inhibitors (DPP4-I): these classes of drugs not only have the ability to reduce blood glucose, but also can exert several cardioprotective effects. They have been shown to positively influence some risk factors for cardiovascular disease (CVD), to improve endothelial function, and to directly affect cardiac function. For these reasons incretins are considered not only antidiabetic drugs, but also cardiovascular effective. The first clinical trials aimed to demonstrate the safety of DPP4 inhibitors have been recently published: their clinical significance will be discussed in light of the prior experimental findings.

Keywords

GLP-1 receptor antagonistDipeptidyl-peptidase 4 inhibitorDiabetesTreatmentCardiovascular diseaseIncretin-based pharmacotherapy

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Angelo Avogaro
    • 1
  • Saula Vigili de Kreutzenberg
    • 1
  • Gian Paolo Fadini
    • 1
  1. 1.Malattie del Metabolismo, Dipartimento di Medicina-DIMEDUniversità di PadovaPadovaItaly